Registrations:

Transcription

1 Organized by Registrations: CHAIR Rafael Rosell, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona) Under the Auspicies of:

2 Thursday, 17 th November 2011 SESSION 1: EARLY NSCLC Florentino Hernando-Trancho, Hospital Clínico Univ. San Carlos, Madrid 10:30-10:35 Introduction 10:35-10:50 Predictive gene signature Ramón García-Escudero, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid 10:50-11:05 Gene signatures in early NSCLC 11:05-11:20 Modern approaches to customizing adjuvant chemotherapy Michel van den Heuvel, Netherlands Thoracic Institute -Antoni van Leeuwenhoek Hospital, Amsterdam, Holland 11:20-11:35 Molecular analysis of survival signaling pathways from the NATCH trial: A Trans-Atlantic Collaboration Fadlo R. Khuri, Emory University, Atlanta (Georgia), USA 11:35-11:40 Conclusions Florentino Hernando-Trancho, Hospital Clínico Univ. San Carlos, Madrid SESSION 2: PATHOLOGY AND LUNG CANCER BIOLOGY Susana Benlloch, USP Institut Dexeus, Pangaea Biotech, Barcelona Javier de Castro, Hospital Univ. La Paz, Madrid 11:40-11:45 Introduction: relevance of translational research Javier de Castro, Hospital Univ. La Paz, Madrid 11:45-12:00 Molecular advances in lung cancer pathology Santiago Ramón y Cajal, Hospital Univ. Vall d'hebron, Barcelona 12:00-12:15 BRAF mutations in NSCLC Antonio Marchetti, University-Foundation, Chiety, Italy 12:15-12:30 ALK, LKB1 and P130 assessment Mª Luisa Botero, USP Institut Dexeus, Pangaea Biotech, Barcelona 12:30-12:45 p53 mutations in lung cancer Miguel Á. Molina, USP Institut Dexeus, Pangaea Biotech, Barcelona 12:45-13:00 Endothelial circulating cells and microparticles in lung cancer Tania C. Fleitas, Hospital Univ. La Fe, Valencia 13:00-14:15 Lunch

3 SESSION 3: DISCOVERIES IN CANCER BIOLOGY Montserrat Sánchez-Céspedes, Instituto de Investigación Biomédica de Bellvitge, Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona) 14:15-14:30 Mutation screening and biological characterization of BRG1 and other tumor suppressor genes in lung cancer Montserrat Sánchez-Céspedes, Instituto de Investigación Biomédica de Bellvitge, Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona) 14:30-14:45 Keynote Lecture: NF-kB in FAS signaling pathway in tumors with EGFR mutations Trever G. Bivona, University of San Francisco, California, USA 14:45-15:15 Genes involved in chromatin remodeling complex as determinants of sensitivity to ALK and EGFR inhibitors René Bernards, Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Holland 15:15-15:30 AEG-1 and BRCA1 as determinants of outcome to erlotinib in EGFR-mutated NSCLC 15:30-15:45 Break SESSION 4: CUSTOMIZED CLINICAL TRIALS Carlos Camps, Hospital General Universitario, Valencia Bartomeu Massutí, Hospital General Universitario, Alicante Introduction Bartomeu Massutí, Hospital General Universitario, Alicante 15:45-16:00 EURTAC Luis Paz-Ares, Hospital Univ. Virgen del Rocío, Sevilla 16:00-16:15 SCAT José M. Sánchez, Centro Oncológico M.D. Anderson International España, Madrid 16:15-16:30 BREC Carlos Camps, Hospital General Universitario, Valencia 16:30-16:45 BREC-China Jia Wei, Drum Tower Hospital, Nanjing, China 16:45-17:00 Olaparib+gefitinib Rosario García-Campelo, Complejo Hospitalario Universitario, A Coruña 17:00-17:15 Bevacizumab Oliver Gautschi, Bern University Hospital, Bern, Switzerland 17:15-17:40 Coffee Break

4 CLINICAL WORKSHOP Carlos Camps, Hospital General Universitario, Valencia Dolores Isla, Hospital Clínico Univ. Lozano Blesa, Zaragoza 17:40-17:50 Lung cancer in never-smokers: differential issues José M. Trigo, Hospital Clínico Univ. Virgen de la Victoria, Málaga 17:50-18:00 Different endpoints with targeted therapies Manuel Cobo, Hospital Univ. Carlos Haya, Málaga 18:00-18:10 Optimal techniques for early detection of response Alfredo Sánchez, Hospital Provincial de Castellón, Castellón 18:10-18:20 New drugs, new toxicities Ruth Porta, ICO, Hospital Univ. Dr. Josep Trueta, Girona 18:20-18:30 Treatment strategy for advanced squamous carcinoma Margarita Majem, Hospital de la Santa Creu i Sant Pau, Barcelona 18:30-18:40 Selection of patients for maintenance treatment Ana Blasco, Hospital General Universitario, Valencia 18:40-18:50 Treatment for patients resistant to EGFR-TKIs Ramón Palmero, ICO, Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona) 18:50-19:00 The REASON study Bartomeu Massutí, Hospital General Universitario, Alicante 19:00-19:10 Outcomes to pemetrexed in advanced NSCLC: An overview of recent findings Santiago Ponce Aix, Hospital Univ. 12 de Octubre, Madrid 19:10-19:20 Discussion Carlos Camps, Hospital General Universitario, Valencia Dolores Isla, Hospital Clínico Univ. Lozano Blesa

5 Friday, 18 th November :00-08:30 SLCG Plenary Session 08:30-09:00 Plenary Lecture Rafael Rosell, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona) SESSION 5: APPLICABILITY OF TRANSLATIONAL RESEARCH Adolfo G. Favaretto, University Hospital, Padua, Italy 09:00-09:15 mrna expression of genes involved in the EGFR and NF-kB pathways Santiago Viteri, USP Institut Dexeus, Pangaea Biotech, Barcelona 09:15-09:30 NF-kB inhibitors and RAS signalling Haian Fu, Emory University, Atlanta (Georgia), USA 09:30-09:45 The refined BRCA1 model in cisplatin-treated patients Laura Bonanno, Istituto Oncologico Veneto, Padua, Italy 09:45-10:00 Circulating tumor cells Andreas-Claudius Hoffmann, West German Cancer Center, Essen, Germany 10:00-10:15 EGFR in Latin America Andrés F. Cardona, Institute of Oncology, Fundación Santa Fe de Bogotá, Colombia 10:15-10:30 The TOFEM registry Margarita Majem, Hospital de la Santa Creu i Sant Pau, Barcelona 10:30-10:45 Molecular predictive markers for response to bevacizumab: the role of the AMP kinase pathway Stefano Indraccolo, Istituto Oncologico Veneto - IRCCS, Padua, Italy 10:45-11:00 Keynote Lecture: FGFR1 amplification and other targetable alterations in squamous cell carcinoma Roman Thomas, Dana Farber Cancer Institute, Harvard Medical School, Boston (Massachusetts), USA 11:00-11:20 Coffee Break SESSION 6: Chemoradiotherapy Wilfried Eberhardt, West German Cancer Center, Essen, Germany Ferran Guedea, ICO, Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona) 11:20-11:35 Trimodality in stage III NSCLC Wilfried Eberhardt, West German Cancer Center, Essen, Germany 11:35-11:50 Progress in chemoradiotherapy studies Pilar Garrido, Hospital Univ. Ramón y Cajal, Madrid 11:50-12:05 Potential role for customized and targeted therapies in the NSCLC neoadjuvant setting Diego Márquez-Medina, Hospital Arnau de Vilanova, Lleida Yolanda García, Corporaciò Sanitària Parc Taulí, Sabadell (Barcelona) 12:05-12:20 Translational research in stage III NSCLC Joana Spiekermann, West German Cancer Center, Essen, Germany 12:20-12:30 Conclusions Josep Jové, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)

6 SESSION 7: CHAIR: SCLC 12:30-12:45 Optimal approach for limited disease Corinne Finn, The Christie NHS Foundation Trust, Manchester, United Kingdom 12:45-13:00 Treatment of metastatic SCLC Fiona H. Blackhall, The Christie NHS Foundation Trust, Manchester, United Kingdom 13:00-13:15 Molecular research in SCLC: an empty field? Luciano Wannesson, Oncology Institute of Southern Switzerland, Bellinzona, Switerland 13:15-13:30 Conclusions SESSION 8: SPECIAL CASES Rolf A. Stahel, University Hospital, Zurich, Switzerland Alain Vergnenègre, Cluzeau University Hospital, Limoges, France 13:30-13:45 Mesothelioma: state of the art and projects Rolf A. Stahel, University Hospital, Zurich, Switzerland 13:45-14:00 Molecular research in mesothelioma: an empty field? Enric Carcereny, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona) 14:00-14:15 Management of elderly patients Alain Vergnenègre, Cluzeau University Hospital, Limoges, France 14:15-15:15 Lunch SESSION 9: TARGETED THERAPIES AND NOVEL AGENTS Fernando Barata, Centro Hospitalario Coimbra, Coimbra, Portugal Felipe Cardenal, ICO, Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona) Introduction Felipe Cardenal, ICO, Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona) 15:15-15:30 State of the art of clinical trials with novel agents Enriqueta Felip, Hospital Univ. Vall d'hebron, Barcelona 15:30-15:45 The role of the ETOP in clinical trials Rolf A. Stahel, University Hospital, Zurich, Switzerland 15:45-15:55 Cost-efficacy management in the use of EGFR TKIs Ana Clopés, ICO, Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona) 15:55-16:10 Conclusions Fernando Barata, Centro Hospitalario Coimbra, Coimbra, Portugal

7 SESSION 10: SLCG CLINICAL TRIALS Enric Carcereny, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona) Alain Vergnenègre, Cluzeau University Hospital, Limoges, France 16:10-16:15 PHALCIS José M. Sánchez, Centro Oncológico M.D. Anderson International España, Madrid 16:15-16:25 ANGIOMET Eloísa Jantus, Hospital General Universitario, Valencia 16:25-16:45 TARZO Noemí Reguart, Hospital Clínic Universitari, Barcelona 16:45-16:55 RENO Mariano Provencio, Hospital Univ. Puerta de Hierro, Majadahonda (Madrid) 16:55-17:15 LUNGSCAPE Fiona H. Blackhall, The Christie NHS Foundation Trust, Manchester, United Kingdom Keith Kerr, Aberdeen University Medical School, Aberdeen, United Kingdom

8 Venue Hotel Meliá Barcelona 50 Sarriá Av Barcelona (Spain) Language Lectures will be delivered in English or Spanish Organizing & Scientific Committee Carlos Camps, Hospital General Universitario Valencia Felipe Cardenal, ICO, Hospital Duran i Reynals, L Hospitalet de Llobregat (Barcelona) Javier de Castro, Hospital Universitario La Paz, Madrid Manuel Cobo, Hospital Universitario Carlos Haya, Málaga Rosario García Campelo, Complejo Hospitalario Universitario, A Coruña Florentino Hernando-Trancho, Hospital Clínico Universitario San Carlos, Madrid Dolores Isla, Hospital Clínico Universitario Lozano Blesa, Zaragoza Eloisa Jantús, Hospital General Universitario, Valencia Margarita Majem, Hospital de la Santa Creu i Sant Pau, Barcelona Bartomeu Massutí, Hospital General Universitario, Alicante Luis Paz Ares, Hospital Universitario Virgen del Rocío, Seville Mariano Provencio, Hospital Universitario Puerta de Hierro, Majadahonda (Madrid) Noemí Reguart, Hospital Clínic Universitari, Barcelona Rafael Rosell, ICO, Hospital Universitario Germans Trias i Pujol, Badalona (Barcelona) José Javier Sánchez, Universidad Autónoma de Madrid José Miguel Sánchez, Centro Oncológico MD Anderson International,Madrid Miquel Taron, ICO, Hospital Universitario Germans Trias i Pujol, Badalona (Barcelona) Credits Accredited by the European Society for Medical Oncology Educational Committee Working Group for its medical oncology certification approval program with 13 ESMO-MORA category 1 points. Accreditation requested to the "Consell Català de Formació Continuada de les Professions Sanitàries" Supporting Companies AstraZeneca Lilly Roche Amgen Bayer Schering Pharma Boehringer Ingelheim GlaxoSmithKline Merck Sharp & Dohme Novartis Pierre Fabre These companies have no influence over the contents of the scientific program Conference Secretariat Doctaforum Congresos y Reuniones Científicas Monasterios de Suso y Yuso 34, Madrid Tel.: Fax: